Yahoo Finance6d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the ...
TV 2 Nyheder3d
Novo Nordisk fortsætter stort fald
Mens Zealand Pharma kan hæve armene, må stemningen være mere trykket i Bagsværd, hvor Novo Nordisk har hovedkontor. Danmarks suverænt største virksomheder er ...
Finanznachrichten5d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...
TV 2 Nyheder5d
Mavepuster til Novo Nordisk
Danmarks mest værdifulde virksomhed, Novo Nordisk, har fået skåret omkring en tiendedel af sin værdi væk i løbet af dagen. I ...
DR5d
Studie af Novos nye fedme-blockbuster viser 'overlegen effektivitet' - alligevel falder aktien massivt
Studie af Novos nye fedme-blockbuster viser 'overlegen effektivitet' - alligevel falder aktien massivt Danmarks mest ...
Berlingske5d
Novo dykker stort efter nye fedmeresultater
Aktiekursen for Novo Nordisk er øjeblikkeligt begyndt at falde, efter at den danske medicinalgigant har offentliggjort nye ...
Yahoo3d
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen ...
Market Inference5d
Here's What You May Have Missed About Novo Nordisk A/S(NVO)
One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...
ncbiotech.org3d
Novo Nordisk Breaks Ground for $1.8B Drug Plant in Clayton
Novo Nordisk, headquartered in Bagsvaerd, Denmark, is a global healthcare company with more than 90 years in diabetes care and additional experience in developing treatments for other serious chronic ...
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...